Overview:

Summary

Global Markets Direct’s, 'Familial Adenomatous Polyposis Coli - Pipeline Review, Q2 2011', provides an overview of the Familial Adenomatous Polyposis Coli therapeutic pipeline. This report provides information on the therapeutic development for Familial Adenomatous Polyposis Coli, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Adenomatous Polyposis Coli. 'Familial Adenomatous Polyposis Coli - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Familial Adenomatous Polyposis Coli.
- A review of the Familial Adenomatous Polyposis Coli products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Familial Adenomatous Polyposis Coli pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Familial Adenomatous Polyposis Coli.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis Coli pipeline depth and focus of Familial Adenomatous Polyposis Coli therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Familial Adenomatous Polyposis Coli Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Familial Adenomatous Polyposis Coli 7
Familial Adenomatous Polyposis Coli Therapeutics under Development by Companies 9
Familial Adenomatous Polyposis Coli Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Familial Adenomatous Polyposis Coli Therapeutics - Products under Development by Companies 13
Familial Adenomatous Polyposis Coli Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Familial Adenomatous Polyposis Coli Therapeutics Development 15
MDRNA, Inc. 15
S.L.A. Pharma AG 15
Familial Adenomatous Polyposis Coli - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
CEQ508 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Eicosapentaenoic Acid 99% - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Aspirin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Sulindac + Tarceva - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Tarceva + Sulindac - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Familial Adenomatous Polyposis Coli Therapeutics – Drug Profile Updates 28
Familial Adenomatous Polyposis Coli Therapeutics - Discontinued Products 30
Familial Adenomatous Polyposis Coli - Featured News 31
Apr 20, 2011: Marina Biotech Completes Enrollment Of First Cohort In START-FAP Clinical Trial Of CEQ508 31
Apr 12, 2011: Pfizer Announces Encouraging Data From Open-Label Extension Study Of Tafamidis 31
Apr 07, 2011: Marina Biotech Initiates Dosing In Phase Ib/IIa START-FAP Clinical Trial Of CEQ508 32
Apr 04, 2011: Marina Biotech Presents Long Term Toxicology Data For CEQ508 FAP Drug Candidate 33
Mar 14, 2011: Marina Biotech Announces First Patient Enrollment In Familial Adenomatous Polyposis Clinical Trial 33
Feb 24, 2011: Marina Biotech Reports Interim Results From Phase II-Enabling Toxicology Study For CEQ508 34
Dec 29, 2010: Marina Biotech Receives Orphan Drug Designation For CEQ508 In Treatment Of Familial Adenomatous Polyposis 35
Nov 03, 2010: Marina Biotech Announces Clinical Protocol Approval Of CEQ508 At Massachusetts General Hospital 36
Oct 26, 2010: Marina Biotech Announces Interim Safety Results Of Long-Term Toxicology Study 36
Mar 07, 2008: Pfizer wins challenge to two main U.S. patents for Celebrex by generic manufacturer Teva 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 39
Contact Us 39
Disclaimer 39"

List of Tables
Number of Products Under Development for Familial Adenomatous Polyposis Coli, Q1 2011 7
Products under Development for Familial Adenomatous Polyposis Coli – Comparative Analysis, Q1 2011 8
Number of Products under Development by Companies, Q1 2011 9
Number of Products under Investigation by Universities/Institutes, Q1 2011 10
Comparative Analysis by Late Stage Development, Q1 2011 11
Comparative Analysis by Mid Clinical Stage Development, Q1 2011 12
Products under Development by Companies, Q1 2011 13
Products under Investigation by Universities/Institutes, Q1 2011 14
MDRNA, Inc., 2011 15
S.L.A. Pharma AG, 2011 15
Assessment by Monotherapy Products, Q1 2011 16
Assessment by Combination Products 17
Assessment by Stage and Route of Administration, Q1 2011 19
Assessment by Molecule Type, Q1 2011 21
Familial Adenomatous Polyposis Coli Therapeutics – Drug Profile Updates 28
Discontinued Products 30"

List of Figures
Number of Products under Development for Familial Adenomatous Polyposis Coli, Q1 2011 7
Products under Development for Familial Adenomatous Polyposis Coli – Comparative Analysis, Q1 2011 8
Products under Development by Companies, Q1 2011 9
Products under Investigation by  Universities/Institutes, Q1 2011 10
Late Stage Products, Q1 2011 11
Mid Clinical Stage Products, Q1 2011 12
Assessment by Monotherapy Products, Q1 2011 16
Assessment by Combination Products, Q1 2011 17
Assessment by Route of Administration, Q1 2011 18
Assessment by Stage and Route of Administration, Q1 2011 19
Assessment by Molecule Type, Q1 2011 20
Assessment by Stage and Molecule Type, Q1 2011 21